CorroHealth signed definitive agreements for a strategic investment from Patient Square Capital. Current shareholders, including investment funds affiliated with global investment firm Carlyle (CG), TT Capital Partners, Sanaka Group, and CorroHealth management, will remain investors, with Patient Square and Carlyle sharing joint control of CorroHealth. Carlyle has been the majority investor in CorroHealth since 2019 and a predecessor business since 2017. The transaction is expected to close by the end of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CG:
- Carlyle price target raised to $47 from $45 at Evercore ISI
- Carlyle price target raised to $50 from $46 at Morgan Stanley
- Advance Auto Parts (AAP) Stock Is Down 23% Amid Financial Headwinds
- Carlyle price target raised to $50 from $46 at Barclays
- Opening Day: StandardAero surges in market debut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
